Dr. Scott Losk
Claim this profileSummit Research Network
Studies Alzheimer's Disease
Studies Dementia
8 reported clinical trials
8 drugs studied
Affiliated Hospitals
Clinical Trials Scott Losk is currently running
Donanemab
for Alzheimer's Disease
This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.
Recruiting1 award Phase 34 criteria
GSK4527226
for Early Alzheimer's Disease
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment \[MCI\] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Recruiting0 awards Phase 214 criteria
More about Scott Losk
Clinical Trial Related4 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Scott Losk has experience with
- Placebo
- ATH-1017
- Donanemab
- Buntanetap
- Simufilam
- Remternetug (IV)
Breakdown of trials Scott Losk has run
Alzheimer's Disease
Dementia
Alzheimer's Dementia
Parkinson's Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Scott Losk specialize in?
Scott Losk focuses on Alzheimer's Disease and Dementia. In particular, much of their work with Alzheimer's Disease has involved treating patients, or patients who are undergoing treatment.
Is Scott Losk currently recruiting for clinical trials?
Yes, Scott Losk is currently recruiting for 4 clinical trials in Portland Oregon. If you're interested in participating, you should apply.
Are there any treatments that Scott Losk has studied deeply?
Yes, Scott Losk has studied treatments such as Placebo, ATH-1017, Donanemab.
What is the best way to schedule an appointment with Scott Losk?
Apply for one of the trials that Scott Losk is conducting.
What is the office address of Scott Losk?
The office of Scott Losk is located at: Summit Research Network, Portland, Oregon 97210 United States. This is the address for their practice at the Summit Research Network.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.